Display options
Cite
Hammarsten O, Muslimovic A, Thunström S, et al. Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C. Cytometry B Clin Cytom. 2020;100(3):370-376doi: 10.1002/cyto.b.21950.
Hammarsten, O., Muslimovic, A., Thunström, S., Ek, T., & Johansson, P. (2021). Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C. Cytometry. Part B, Clinical cytometry, 100(3), 370-376. https://doi.org/10.1002/cyto.b.21950
Hammarsten, Ola, et al. "Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C." Cytometry. Part B, Clinical cytometry vol. 100,3 (2021): 370-376. doi: https://doi.org/10.1002/cyto.b.21950
Hammarsten O, Muslimovic A, Thunström S, Ek T, Johansson P. Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C. Cytometry B Clin Cytom. 2021 May;100(3):370-376. doi: 10.1002/cyto.b.21950. Epub 2020 Aug 28. PMID: 32857894; PMCID: PMC8246776.
Copy Download .nbib Format: NLM
Share it on

Cytometry B Clin Cytom. 2021 May;100(3):370-376. doi: 10.1002/cyto.b.21950. Epub 2020 Aug 28.

Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C.

Cytometry. Part B, Clinical cytometry

Ola Hammarsten, Aida Muslimovic, Sofia Thunström, Torben Ek, Pegah Johansson

Affiliations

  1. Department of Laboratory Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  2. Laboratory of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden.
  3. Clinical Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden.
  4. Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
  5. Children's Cancer Centre, Queen Silvia Children's Hospital, Gothenburg, Sweden.

PMID: 32857894 PMCID: PMC8246776 DOI: 10.1002/cyto.b.21950

Abstract

The recently reported cell division assay (CDA) was optimized to measure the relative sensitivity of cells to cytotoxic drugs in vitro. Here, we investigated the in vitro hypersensitivity of lymphocytes from Fanconi anemia (FA) patients, to cytotoxic drugs using CDA. Peripheral blood mononuclear cells (PBMC) as well as cell lines derived from FA patients were treated with two DNA interstrand crosslinking (ICL) agents, mitomycin C and cyclophosphamide. Our data indicate that the CDA detects hypersensitivity of cells from FA patients to mitomycin C. Further, cell lines derived from FA-patients were also hypersensitive to mitomycin C as well as cyclophosphamide, when assayed by the CDA. This study suggests that the CDA is a useful alternative for the diagnosis of FA patients' hypersensitivity to ICL agents.

© 2020 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.

Keywords: DNA interstrand crosslinking (ICL) agents; Fanconi anemia (FA); cell division assay (CDA); flow cytometry; mitomycin C

References

  1. Biol Blood Marrow Transplant. 2016 Jul;22(7):1257-1263 - PubMed
  2. Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):198-204 - PubMed
  3. DNA Repair (Amst). 2018 Jan;61:17-24 - PubMed
  4. Expert Rev Hematol. 2017 Jan;10(1):81-97 - PubMed
  5. Blood Rev. 2010 May;24(3):101-22 - PubMed
  6. Pediatr Blood Cancer. 2006 Apr;46(4):496-500 - PubMed
  7. Am J Med Genet. 1997 Jan 10;68(1):58-61 - PubMed
  8. Blood. 1995 Apr 15;85(8):2233-7 - PubMed
  9. Front Oncol. 2019 May 22;9:420 - PubMed
  10. Nature. 1975 Dec 4;258(5534):427-9 - PubMed
  11. Br J Haematol. 2010 Apr;149(1):14-21 - PubMed
  12. Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4): - PubMed
  13. Cytometry B Clin Cytom. 2021 May;100(3):370-376 - PubMed
  14. Mutat Res. 1999 Sep 13;435(1):103-9 - PubMed
  15. Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2415-20 - PubMed
  16. Br J Haematol. 2006 Apr;133(2):188-97 - PubMed
  17. Clin Biochem. 2016 May;49(7-8):566-72 - PubMed
  18. BMC Res Notes. 2018 Aug 3;11(1):558 - PubMed
  19. Anemia. 2012;2012:238731 - PubMed
  20. Eur J Cancer. 1992;28A(11):1783-91 - PubMed
  21. Mutat Res. 2009 Jul 31;668(1-2):73-91 - PubMed
  22. F1000Prime Rep. 2014 Apr 01;6:23 - PubMed
  23. Cancer. 2003 Jan 15;97(2):425-40 - PubMed
  24. Nat Rev Cancer. 2018 Mar;18(3):168-185 - PubMed
  25. Angew Chem Int Ed Engl. 2002 Jul 15;41(14):2596-9 - PubMed
  26. Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):214-21 - PubMed
  27. J Pediatr Hematol Oncol. 2019 Nov;41(8):612-617 - PubMed
  28. Cancer Res. 1982 Oct;42(10):4000-6 - PubMed
  29. Hum Mutat. 2014 Nov;35(11):1342-53 - PubMed
  30. Pediatr Ann. 2015 Oct;44(10):444-5, 448, 450 passim - PubMed
  31. Mutat Res. 2009 Jul 31;668(1-2):4-10 - PubMed
  32. Pediatrics. 1993 Jun;91(6):1116-20 - PubMed
  33. Nat Rev Cancer. 2011 Jun 24;11(7):467-80 - PubMed
  34. N Engl J Med. 1989 Jul 13;321(2):120-1 - PubMed
  35. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1569-74 - PubMed
  36. Leuk Res. 2012 Jan;36(1):29-31 - PubMed
  37. J Pediatr Hematol Oncol. 1999 May-Jun;21(3):240-3 - PubMed
  38. Annu Rev Biophys. 2014;43:257-78 - PubMed

Publication Types